BOTHELL, WA, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), announces promising in vitro and 7-day toxicity data for its influenza A preclinical lead molecule, CC-42344, that is currently being evaluated in IND-enabling studies for the treatment of both seasonal and pandemic influenza strain A.

https://www.channelchek.com/news-channel/Release___Cocrystal_Pharma__COCP____Cocrystal_Pharma_Provides_Update_on_Influenza_A_Program